Danaher Corporation ($DHR) Stock Forecast: Down 4.2% Today

What is Danaher Corporation?

Danaher Corporation (DHR) operates in the healthcare and life science tools sector and has a market capitalization of $155.504 billion.

Why is Danaher Corporation going down?

DHR stock is down 4.2% on Feb 12, 2026 16:27

• Recent bearish movement in Danaher Corporation's stock could be due to several factors:
• Wealthfront Advisers LLC reduced its stake in DHR by 21.2% in the third quarter, leading to uncertainty among institutional investors and impacting market sentiment negatively.
• Despite strong quarterly earnings and a "Moderate Buy" rating from analysts, exits by notable investors like RFG Advisory LLC and Wallace Weitz may have contributed to the stock's decline.
• The life science tools sector, facing challenges such as constrained biotechnology funding and pricing pressures in China, as noted by the Baron Durable Advantage Fund, could have added to the bearish sentiment surrounding DHR.
• While Danaher Corporation's long-term value and competitive advantages are acknowledged, market reaction may reflect industry challenges and the changing positions of institutional investors in the company.

DHR Price Chart

DHR Technical Analysis

DHR News

Wallace Weitz Exits CarMax Inc, Impacting Portfolio by -1.58%

Wallace Weitz submitted his 13F filing for Q4 2025, revealing significant changes to his portfolio. He completely exited four holdings, most notably CarMax Inc (KMX), and reduced stakes in 17 others, including Charter Communications Inc (CHTR) and Alphabet Inc (GOOG). Conversely, he added Euronet Worldwide Inc (EEFT) and increased positions in 12 stocks, with the largest increase in Liberty Broadband Corp (LBRDK).

https://www.gurufocus.com/news/8610905/wallace-weitz-exits-carmax-inc-impacting-portfolio-by-158

Baron Durable Advantage Fund Bets on Danaher Corporation (DHR) During Cyclical Challenges

The Baron Durable Advantage Fund increased its position in Danaher Corporation (DHR) despite the company facing cyclical challenges in the life science tools sector, such as constrained biotechnology funding, reduced NIH funding, and pricing pressures in China. The fund sees long-term value in Danaher, a healthcare and life science tools company, focusing on its strong competitive advantages and consistent shareholder returns, while acknowledging current headwinds. Danaher's stock closed at $219.98 on February 11, 2026, with a market capitalization of $155.504 billion, and was held by 117 hedge funds at the end of Q3 2025.

https://www.insidermonkey.com/blog/baron-durable-advantage-fund-bets-on-danaher-corporation-dhr-during-cyclical-challenges-1694226/

Wealthfront Advisers LLC Has $8.10 Million Stock Holdings in Danaher Corporation $DHR

Wealthfront Advisers LLC significantly reduced its stake in Danaher Corporation by 21.2% in the third quarter, now holding 40,844 shares valued at $8.10 million. Despite this, institutional investors collectively own 79.05% of Danaher, with several major funds adding to their positions. Danaher also reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" rating from analysts.

https://www.marketbeat.com/instant-alerts/filing-wealthfront-advisers-llc-has-810-million-stock-holdings-in-danaher-corporation-dhr-2026-02-12/

There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings

Bio-Techne Corporation (NASDAQ:TECH) recently reported earnings that were weaker than expected due to a significant US$155m expense classified as an "unusual item." Simply Wall St analysis suggests that despite the statutory profit being lower, the underlying earnings potential of the company might be stronger than it appears, as these unusual items are typically one-off. Investors are encouraged to look beyond the reported profit and consider other factors like margins, growth forecasts, and return on investment while being aware of the associated risks.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/there-may-be-some-bright-spots-in-bio-technes-nasdaqtech-ear

RFG Advisory LLC Has $1.20 Million Stake in Danaher Corporation $DHR

RFG Advisory LLC significantly reduced its stake in Danaher Corporation (NYSE:DHR) by 54.8% in Q3, selling 7,311 shares and holding 6,027 shares valued at approximately $1.20 million. Despite this, other institutional investors have recently acquired positions in Danaher, and company insiders own 11.10% of the stock. Danaher reported strong quarterly earnings, beating analyst estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $253.86.

https://www.marketbeat.com/instant-alerts/filing-rfg-advisory-llc-has-120-million-stake-in-danaher-corporation-dhr-2026-02-12/

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Danaher Corporation Price History

13.00.2026 - DHR Stock was down 2.9%

• The decline in Danaher Corporation's stock today, despite positive earnings and growth projections, may be linked to profit-taking by institutional investors and notable reductions in their stake.
• Insider sales by company executives, including SVP Brian W. Ellis and Director Teri List, could also have played a role in the stock's downward trend.
• Market reaction might be influenced by reports of Danaher Corp. co-founder Mitch Rales spearheading a significant funding round for VieCure, diverting attention from the company's core operations and creating uncertainty for investors.
• While Danaher continues to demonstrate strong financial performance and provide optimistic guidance for the future, recent developments in institutional holdings and external investments may have instigated bearish sentiment in the market today.

21.09.2025 - DHR Stock was up 6.3%

• Danaher (DHR) reported Q3 earnings and sales that surpassed expectations, with a significant increase in Life Sciences sales compared to the previous year.
• The strong segment growth and enhanced operating margins contributed to the favorable financial results, indicating effective management and strong market demand for the company's offerings.
• Optimistic assessments and future forecasts from financial analysts prior to the earnings announcement likely influenced investor confidence in Danaher's performance, leading to a positive upward trend in the stock price.
• In summary, the robust Q3 results and promising outlook indicate that Danaher's strategic initiatives and market positioning are well-received by investors, prompting a rise in the stock value.

21.09.2025 - DHR Stock was up 11.0%

• Danaher (DHR) reported Q3 earnings and revenues that surpassed expectations, reflecting strong financial performance.
• Analyst insights prior to the earnings announcement likely bolstered investor confidence in the company's growth prospects.
• Despite initial doubts, Danaher's positive earnings and optimistic future outlook drove the stock's upward momentum as investors reassessed the company's potential for success.

05.00.2026 - DHR Stock was up 0.4%

• Danaher's strategic shift towards higher-margin life sciences and diagnostics is positively impacting investor sentiment and driving the bullish movement.
• The increased stake by Railway Pension Investments Ltd signals confidence in Danaher's future prospects and strong Q3 earnings performance.
• Despite potential risks from early-stage biotech funding weakness, the company's focus on profitable segments and positive analyst ratings are contributing to the stock's upward momentum.
• Overall, the market seems optimistic about Danaher's growth potential and strategic direction, leading to the bullish movement in its stock price.

13.10.2025 - DHR Stock was up 3.4%

• Danaher (DHR) observed a bullish movement today, potentially linked to investors acknowledging its value relative to its competitor Solventum (SOLV).
• Comparative analysis between SOLV and DHR could explain the heightened interest in DHR, resulting in increased buying activity.
• Investors might have identified DHR as the more advantageous stock at present, propelling its price upward.
• The optimistic outlook on DHR's potential value likely played a role in its significant bullish movement today.

02.00.2026 - DHR Stock was up 1.5%

• The bullish movement in Danaher's stock can be attributed to the positive market outlook for bioprocess filtration and single-use bioprocessing products, with recent reports projecting significant market growth driven by increasing demand for biologics and advanced therapies.
• Vanderbilt University acquiring a substantial number of shares in Danaher Corporation further boosted investor confidence, indicating strong institutional interest in the company's performance and potential.
• Danaher's solid Q3 earnings report, surpassing analyst expectations for both earnings per share and revenue, coupled with the announcement of a quarterly dividend, likely contributed to the positive sentiment surrounding the stock.
• The recognition of Danaher as a key player in the bioprocess filtration market alongside competitors like Merck and Sartorius underscores the company's position as a leader in the industry, attracting both investor attention and market confidence.

21.04.2025 - DHR Stock was down 5.1%

• The bearish movement in DHR stock today could be due to profit-taking by investors following a recent increase in the stock price.
• The significant decline in the stock price over the past year might also have influenced bearish sentiment among investors.
• Insights from the P/E ratio reveal a decrease of 25.98% in the last year, potentially adding to selling pressure on the stock.
• Investor caution could be stemming from the mixed performance of the stock despite recent gains, prompting a bearish market movement today.

28.00.2026 - DHR Stock was down 5.1%

• Danaher Corp's Q4 2025 earnings showed a mixed outcome, surpassing expectations in EPS but missing revenue targets. This led to a 1.4% decline in the company's shares.
• The strong performance in the bioprocessing business and positive earnings were overshadowed by the slight revenue miss, which might have sparked concerns among investors.
• Analysts are bullish on Danaher Corp's growth trajectory for 2026, with revenue and EPS projections indicating a return to growth that could potentially restore investor confidence.
• Investor sentiment following the earnings announcement underscored a focus on revenue metrics and a cautious stance on the company's future prospects, contributing to the downward movement in DHR stock.

12.01.2026 - DHR Stock was down 4.2%

• Recent bearish movement in Danaher Corporation's stock could be due to several factors:
• Wealthfront Advisers LLC reduced its stake in DHR by 21.2% in the third quarter, leading to uncertainty among institutional investors and impacting market sentiment negatively.
• Despite strong quarterly earnings and a "Moderate Buy" rating from analysts, exits by notable investors like RFG Advisory LLC and Wallace Weitz may have contributed to the stock's decline.
• The life science tools sector, facing challenges such as constrained biotechnology funding and pricing pressures in China, as noted by the Baron Durable Advantage Fund, could have added to the bearish sentiment surrounding DHR.
• While Danaher Corporation's long-term value and competitive advantages are acknowledged, market reaction may reflect industry challenges and the changing positions of institutional investors in the company.

22.06.2025 - DHR Stock was down 1.3%

• Earnings and revenue figures for Q2 exceeded expectations for Danaher (DHR), with market volatility potentially linked to concerns in the Life Sciences area.
• Strong performance in the Biotechnology & Diagnostics divisions alongside the recent acquisition of Abcam are viewed as factors that could drive future growth for the company.
• Analyst commentary on Q2 performance metrics for Danaher (DHR) may have impacted market sentiment, contributing to the stock's downward movement today.

23.06.2025 - DHR Stock was up 5.0%

• Danaher showed strong bullish movement today following its impressive Q2 earnings, where it exceeded sales and EPS estimates, demonstrating robust performance in its biotech segment.
• The company's positive outlook for 2025, driven by biotech growth and cost discipline, has boosted investor confidence, resulting in a rise in the stock price.
• Analysts' optimistic views and projections for Danaher's key performance indicators further reinforce the positive sentiment surrounding the stock, pointing towards a promising future in the biotechnology and diagnostics sectors.

30.08.2025 - DHR Stock was up 5.2%

• Danaher Inc.'s stock price surged by 1.05% today, reflecting strong bullish momentum.
• Despite recent declines over the past month and year, today's uptick indicates a resurgence of investor confidence.
• The rise in stock price could be linked to potential undervaluation, prompting shareholders to seize the opportunity.
• Investors show optimism regarding Danaher's future prospects and growth across its various business segments, propelling the stock price upwards.